姓名 |
張芷瑄(Chi-Hsuan Chang)
查詢紙本館藏 |
畢業系所 |
統計研究所 |
論文名稱 |
利用參數模型探討三臂非劣性試驗所需樣本數
|
相關論文 | |
檔案 |
[Endnote RIS 格式]
[Bibtex 格式]
[相關文章] [文章引用] [完整記錄] [館藏目錄] 至系統瀏覽論文 (2026-7-1以後開放)
|
摘要(中) |
三臂試驗設計包含實驗組、對照組以及安慰劑組,又可以稱為黃金標準設計,這種試驗設計除了可以比較實驗組與對照組外,分別對於安慰劑組的藥效和療效也可以從試驗中得知。本篇研究目的為在三臂非劣性試驗中,以存活時間為主要目標,採用參數比例風險模型 (proportional hazards model,PH),包含weibull、Loglogistic、Rayleigh、Gompertz分配,用來探討各治療組別樣本最佳分配比例以及最佳樣本數,並確認相對的檢定力是否達到預設值。本研究也透過結腸癌資料集去說明與闡述本篇論文所適用的方法。 |
摘要(英) |
The three-arm trial design includes an experimental group, a control group, and a placebo group, also known as a gold standard design. This type of trial design allows for comparison not only between the experimental and control groups but also provides information about the efficacy and therapeutic effects of the placebo group. The purpose of this study is to utilize the three-arm non-inferiority trial, with the primary objective being survival time. The study adopts the proportional hazards model (PH) with various distributions such as Weibull, Loglogistic, Rayleigh, and Gompertz, to explore the optimal allocation proportions and sample sizes for each treatment group. Additionally, it aims to verify whether the corresponding test power meets the predetermined value. This study also utilizes a colon cancer dataset to demonstrate and elaborate on the methods applicable to this research paper. |
關鍵字(中) |
★ 三臂試驗 ★ 非劣性 ★ PH模型 ★ 最佳樣本數 |
關鍵字(英) |
★ Non-inferiority ★ optimal sample size ★ proportional hazards (PH) model ★ Three-arm trial |
論文目次 |
摘要(I)
Abstract(II)
致謝(III)
目錄(IV)
表目錄(VI)
圖目錄(VII)
第一章 緒論(p.1)
第二章 研究方法(p.12)
第三章 模擬研究(p.20)
第四章 實際資料分析(p.45)
第五章 討論與結論(p.53)
參考文獻(p.55)
附錄(p.56) |
參考文獻 |
1.Efron, B. (1977). The efficiency of Cox’s likelihood function for censored data. Journal of the American Statistical Association. 72, 557–565.
2.Gamalo MA, Wu R and Tiwari RC. (2016). Bayesian approach to non-inferiority trials for normal means. Statistical Methods in Medical Research. 25, 221–40.
ibitem{Mielke}
3.Mielke, M., Munk, A. and Schacht, A. (2008). Planning and assessing non-inferiority in a
gold standard design with censored,exponentially distributed endpoints. Statistics in
Medicine. 27, 5093–5110.
4.Chang, Y.-W., Y. Tsong and Z. Zhao. (2017). Sample size determination for a three-arm equivalence trial of passion and negative binomial responses. Journal of Biopharmaceutical Statistics. 27, 239–256.
6.Carreras M and Brannath W. (2013). Shrinkage estimation in two-stage adaptive designs with midtrial treatment selection. Statistics in
Medicine. 32, 1677–90.
7.Homma G., Diamon T. (2021). Sample size calculation for "Gold-standard" noninferiority trials with fixed margins and negative binomial endpoints.
Statistics in Biopharmaceutical Research. 13, 435- 447.
8.Karola, K., Axel, M. and Tim, F. (2013). Design and semiparametric analysis of non-inferiority trials with active and placebo control for censored time-to-event data.
Statistics in Medicine. 32, 3055–3066.
9.林建甫(2008)。存活分析。台北市:雙葉書廊出版。
10.如何估計優越性、等效性及非劣性臨床試驗所需之樣本數。醫學研究部(Department of Medical Research),共同研究室電子報第七十期。
11.衛生福利部朴子醫院檢查中心(2016)。認識大腸癌。取自:https://www.puzih.mohw.gov.tw/?aid=509& pid=0&page\_name=detail
&iid=757 |
指導教授 |
曾議寬(Yi-Kuan Tseng)
|
審核日期 |
2023-7-11 |
推文 |
facebook plurk twitter funp google live udn HD myshare reddit netvibes friend youpush delicious baidu
|
網路書籤 |
Google bookmarks del.icio.us hemidemi myshare
|